11 November 2020 - Surface Oncology today announced that the U.S. FDA has granted fast track designation to SRF388 for the treatment of patients with hepatocellular carcinoma, or liver cancer, who have been previously treated with standard therapies, such as vascular endothelial growth factor targeted agents and programmed death-ligand blockade.
SRF388 recently received orphan drug designation for treatment of hepatocellular carcinoma from the FDA.